30 Apr Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation
Posted at 14:04h
in
Key Oncologies (Pty) Ltd, as directed by the South African Health Products Regulatory Authority (SAHPRA), wish to inform you about the risk of thrombosis, including cerebral infarction, upon abrupt treatment discontinuation of anagrelide hydrochloride.
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
30/04/2025
File Type:
pdf
Category:
Communication To Health Care Professionals